retatrutide doses clinical trial Dosing Guide: 2mg–12mg Protocol + Calculator retatrutide clinical trial dosing frequency

According to the American Diabetes Association , studies comparing GLP-1 medications have demonstrated significant weight loss potential for both semaglutide and tirzepatide

Cardiovasc Saf Trials all New Diabetes Mellitus Drugs

10.1093/eurheartj/ehaa575 10 CreaF.CamiciP

GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone